Braveheart Bio
BRVE
18.58
-1.21
-6.11%
Braveheart Bio
US · BRVE
#2845 by market cap
Listed 2026
18.58
-1.21
-6.11%
Live - 5344 symbols - heartbeat 226s ago
· 2026-10-08 07:00
Pre-market
18.58
0.00%
After-hours
18.58
0.00%
- Market cap
- 1.67B
- P/E (TTM)i
- -3.01
- P/Bi
- -17.45
- EPSi
- -0.94
- Div yieldi
- 0.00%
- 52W posi
- 1%
Reader sentiment
Are you bullish or bearish on BRVE?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 1 years
Income statement
| Line item | 2025 |
|---|---|
| Revenue | -- |
| Gross profit | -- |
| Selling & admin expenses | 3.02M |
| Research & development | 1.49M |
| Operating profit | -4.51M |
| Pretax profit | -66.05M |
| Tax | -- |
| Net profit | -66.05M |
| Basic EPS | -5 |
| Diluted EPS | -5.32 |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| Revenue | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- |
| Selling & admin expenses | 5.00K | 27.00K | 4.14M | 4.76M |
| Research & development | 0 | 0 | 10.91M | 11.13M |
| Operating profit | -5.00K | -27.00K | -15.05M | -15.88M |
| Pretax profit | -99.00K | -381.00K | -14.28M | -14.99M |
| Tax | -- | -- | -- | -- |
| Net profit | -99.00K | -381.00K | -14.28M | -14.99M |
| Basic EPS | 0 | 0 | 0 | 0 |
| Diluted EPS | 0.00 | -0.01 | -0.33 | -0.30 |
Balance sheet
| Line item | 2025 |
|---|---|
| Total current assets | 89.28M |
| Cash & ST investments | 89.16M |
| Inventory | -- |
| Total assets | 89.35M |
| Total current liabilities | 5.24M |
| Short-term debt | -- |
| Long-term debt | -- |
| Total liabilities | 155,222,000.00 |
| Total equity | -65.87M |
| Retained earnings | -66.05M |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| Total current assets | -- | -- | 81.07M | 123.45M |
| Cash & ST investments | -- | -- | 80.58M | 122.83M |
| Inventory | -- | -- | -- | -- |
| Total assets | -- | -- | 81.88M | 126.96M |
| Total current liabilities | -- | -- | 10.00M | 9.06M |
| Short-term debt | -- | -- | 373.00K | 377.00K |
| Long-term debt | -- | -- | -- | -- |
| Total liabilities | -- | -- | 160,270,000.00 | 222,862,000.00 |
| Total equity | -- | -- | -78.39M | -95.91M |
| Retained earnings | -- | -- | -80.33M | -95.91M |
Cash flow
| Line item | 2025 |
|---|---|
| Operating cash flow | -2.01M |
| Depreciation & amortization | -- |
| Free cash flow | -35.58M |
| Dividends paid | -- |
| Stock buybacks / issuance | 95.00K |
| Ending cash balance | 89.16M |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| Operating cash flow | 0 | 0 | -5.19M | -16.95M |
| Depreciation & amortization | 0 | 0 | 2.00K | 3.00K |
| Free cash flow | 0 | 0 | -8.22M | -16.94M |
| Dividends paid | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- |
| Ending cash balance | 0 | 2.00K | 80.58M | 122.83M |
Returns & efficiency
| Line item | 2025 |
|---|---|
| ROE %i | -- |
| ROA %i | -73.93 |
| ROIC %i | -- |
| 5-year avg ROE %i | -- |
| EBIT margin %i | -- |
| FCF / sales %i | -- |
| Current ratioi | 17.03 |
| Quick ratioi | 17.01 |
| Debt / assetsi | -- |
| LT debt / equityi | -- |
| Interest coveragei | -- |
| Revenue CAGR (3Y) %i | -- |
| Net income CAGR (3Y) %i | -- |
| FCF CAGR (3Y) %i | -- |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| ROE %i | -- | -- | -- | -- |
| ROA %i | -- | -- | -97.99 | -77.55 |
| ROIC %i | -- | -- | -- | -- |
| 5-year avg ROE %i | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- |
| Current ratioi | -- | -- | 8.11 | 13.63 |
| Quick ratioi | -- | -- | 8.06 | 13.56 |
| Debt / assetsi | -- | -- | 0.81 | 0.45 |
| LT debt / equityi | -- | -- | -- | -- |
| Interest coveragei | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- |
Quote time 2026-10-08 07:00:27 · For reference only, not investment advice and not tailored to your situation.